The Authors studied 120 prostatic cancers in a 16-year retrospective study: 68 of them (57%) were stage D and 32 (29%) stage C tumors. Global survival rate of the case reports related to staging was similar to that reported in literature. There was a statistically significant difference between the survival of the group treated by antiandrogens alone and the group treated by total androgenic blockade. The latter was obtained by orchiectomy plus antiandrogens. The increase of the survival rate in the group treated by total androgenic blockade encourage its use “ab initio” for the treatment of metastatic tumor of the prostate.
HugginsC., and HodgesC.V.: Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1: 293, 1941.
2.
BlackardC.E.: The Veteran Administration Cooperative Urologic Research Group studies of carcinoma of the prostate: a review. Cancer Chemother. Rep.59: 335, 1975.
3.
BrendlerH., and ProutG.R.Jr.: A cooperative group study of prostatic cancer: stilbestrol versus placebo in advanced progressive disease. Cancer Chemother. Rep.16: 323, 1962.
4.
NesbitR.H., and BaumW.C.: Endocrine control of prostatic carcinoma: clinical and statical survey of 1.818 cases. J.A.M.A.143: 1317, 1950.
5.
BoccardoF., De CensiA., GuarneriD.: Il carcinoma della prostata. La terapia medica. Atti Corsi paralleli. Scuola Sup. Oncol. e Scienze Biomed. Genova, 1989.
6.
EmmetL.F., GreeneL.F., PapantoniouA.: Endocrine therapy in carcinoma of the prostate gland, 10 years survival studies. J. Urol.83: 471, 1960.
7.
De VoogtH.J.: De endocrine behandeling van prostaatkanker. Thesis. Utrecht, 1963.
8.
OchiaiJ., TakeuchiH.: Some consideration on rationale for antiandrogenic treatment of advanced prostatic carcinoma. Proc. 16th Cong. SIU2: 256, 1973.
9.
MurphyG.P., BeckleyS., BradyM.F.: Treatment of newly diagnosed prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer51: 1264, 1983.
10.
SmithJ.A.Jr.: New methods of endocrine management of prostatic cancer. J. Urol.137: 1–10, 1987.
11.
MaatmanT.J., GuptaM.K., MontieJ.E.: Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J. Urol.133: 620, 1985.
12.
LabrieF., DupontA., BellangerA., LacoursiereY., RaynaudJ.P., HussonJ.M., GareauJ., FazeksA.T.A., SandowJ., MonfetteG., GirardJ.G., EmondJ., HouleJ.C.: New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. The prostate4: 579, 1983.
13.
LabrieF., DupontA., BelangerA.: Combined treatment with Flutamide and (D-TRP-6) LH-RH ethylamide: fundamental data and 5-year clinical experience. In: “New trends in diagnosis and treatment of prostatic cancer”.GiulianiL., BoccardoF., Eds Acta Medica179–207, 1987.
14.
PaulsonD.F.: Ruolo della terapia endocrina nel trattamento del cancro della prostata. In: “Tumori urogenitali”.SkinnerD.G., LieskovskyG. Eds Saunders Co.500, 1990.
